Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.
Summary
One of the fundamental features of IgA nephropathy (IgAN) is the presence in the circulation of IgA1-containing immune complexes (IgA-IC) with a propensity for mesangial deposition and triggering of glomerular injury [1] . Immune complex formation in IgAN remains a poorly understood process, however Novak and colleagues have over the past 5 years steadily unravelled some of the intricacies, in particular the potential contribution of IgG anti-IgA1 autoantibodies to IgA-IC formation [2] . In contrast to other diseases associated with immune complex formation, immune complexes in IgAN appear to develop as a result of a shift in the distribution of IgA1 O-glycoforms in the serum. In the present paper, Suzuki and colleagues demonstrate IgA1 O-glycoform specific IgG antibodies in the serum of IgAN patients from both USA and Japan. They have gone on to generate B-cell lines from these patients and used the IgG secreted by these cell lines to characterise its specificity. They show that IgG from cells derived from IgAN patients binds poorly galactosylated IgA1 O-glycoforms and in vitro triggers the formation of IgA1-IgG immune complexes. They also present preliminary data suggesting that measurement of IgG with specificity for poorly galactosylated IgA1 may in the future form the basis of a non-invasive diagnostic test for IgAN.
Review of the field
One of the most striking findings in IgAN is an increase in the circulating levels of poorly galactosylated IgA1 O-glycoforms ( Figure 1B ). This has been observed in patient populations from North America, Europe and Asia using a variety of techniques [3] [4] [5] . Importantly, two studies of IgA1 eluted from isolated glomeruli have shown that mesangial IgA is enriched with poorly galactosylated IgA1 Oglycoforms, strongly implicating the composition of IgA1 hinge region glycans in the Translational nephrology mechanism of IgA1 deposition [6, 7] . Novak and colleagues have also reported that these poorly galactosylated IgA1 O-glycoforms are predominantly found in circulating high molecular weight IgA-IC in IgAN [2] . although it is unclear whether this is through antigen-independent hinge region attraction or the presence of O-glycan-specific IgA1 autoantibodies [8] . Once formed there is strong in vitro evidence that IgA-IC display a high affinity for the extracellular matrix components fibronectin and type IV collagen [9] , preferentially bind and activate mesangial cells [10] and activate complement through the alternate and lectin binding pathways [11] . Together these in vitro data support a pathogenic role for circulating IgA-IC in glomerular IgA deposition and mesangial cell activation in IgAN. This is supported by clinical studies which have shown that the distribution "undergalactosylated") but rather there is an increase in "mucosal-type" IgA1 in the serum. We and others reported some 15 years ago that IgAN is indeed associated with a maldistribution of IgA1 secreting plasma cells from mucosal to systemic sites [16, 17] . More recently, changes in the homing of lymphocytes between mucosal and systemic sites has also been reported in IgAN [18, 19] . One possibility therefore is that mucosal IgA1-committed plasma cells are misdirected to systemic sites in IgAN and then secrete "mucosal-type" IgA1 into the circulation -the "right" IgA1 molecules ending up in the "wrong" place ( Figure 2 ).
Immune complex formation in IgAN may similarly be a case of the "right" IgG antibodies being in the "wrong" place at the "wrong" time. Suzuki and colleagues
propose that the IgG anti-IgA1 autoantibodies could in fact be antibodies specific for haematuria. An increase in circulating IgA-IC levels during episodes of macroscopic haematuria has been reported, however, any involvement of molecular mimicry in
IgA-IC formation is at present pure speculation [10, 20] . 
